113,188 Shares in Oruka Therapeutics, Inc. $ORKA Purchased by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the second quarter, Holdings Channel.com reports. The institutional investor bought 113,188 shares of the company’s stock, valued at approximately $10,772,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at about $2,874,000. The Manufacturers Life Insurance Company bought a new position in shares of Oruka Therapeutics in the second quarter worth approximately $6,512,000. Algert Global LLC increased its position in shares of Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after purchasing an additional 180 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Oruka Therapeutics in the second quarter valued at approximately $211,000. Finally, Quantbot Technologies LP purchased a new stake in Oruka Therapeutics in the second quarter valued at approximately $463,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $102.42 on Tuesday. The business has a 50 day moving average of $92.49 and a 200 day moving average of $65.93. The company has a market capitalization of $6.78 billion, a price-to-earnings ratio of -50.45 and a beta of -0.34. Oruka Therapeutics, Inc. has a 1-year low of $14.34 and a 1-year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.27 EPS for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the sale, the insider directly owned 32,718 shares of the company’s stock, valued at $2,266,703.04. The trade was a 19.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Carl Dambkowski sold 22,417 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21. Following the sale, the director owned 51,326 shares of the company’s stock, valued at approximately $3,599,492.38. The trade was a 30.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,116 shares of company stock worth $6,636,533 in the last 90 days. 23.49% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Guggenheim reaffirmed a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, April 30th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $134.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.